CHEK2 and breast cancer: Concluding, unlike previous studies, we found no evidence for significant differences in prognosis in ER-positive CHEK2 c.1100delC-associated breast cancer patients and non-carriers, which could be explained by the more recent years of diagnosis and treatment regimens.